Elevated cerebrospinal fluid substance P-like immunoreactivity in patients with painful osteoarthritis, but not in patients with rhizopatic pain from a herniated lumbar disc

Scandinavian Journal of Rheumatology

Volumn 26, Issue 6, 1997, Pages 468-472

  Lindh, C ^a   Liu, Z ^b   Lyrenas S ^a   Ordeberg, G ^a   Nyberg, F ^b  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Cerebrospinal fluid; Nociceptive pain; Osteoarthritis; Radioimmunoassay; Rhizopatic pain; Substance P

Indexed keywords

SUBSTANCE P;

ARTHRALGIA; ARTICLE; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; ISCHIALGIA; LUMBAR DISK HERNIA; OSTEOARTHRITIS; PAIN ASSESSMENT; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

EID: 0031450220     PISSN: 03009742     EISSN: None     Source Type: Journal    
DOI: 10.3109/03009749709065721     Document Type: Article

References (25)

1. Euler US v, Gaddum JH. An unindentified depressor substance in certain tissue extracts. J Physiol (Lond) 1931;72:74-87.
2. Harmar A, Schofield JG, Keen P. Substance P biosynthesis in dorsal root ganglia: An immunochemical study of [35S]methionine and [3H]-proline incorporation in vitro. Neuroscience 1981;6:1917-22.
3. Pernow B, Substance P. Pharmacol Rev 1983;35:85-141.
4. Saito T. Immunohistochemical study on the effect of high tibial osteotomy on the distribution pattern of neuropeptides in the synovium of the osteoarthritic knee. Nippon Seikeigeka Gakkai Zasshi 1992;66:884-97.
5. Ashton IK, Ashton BA, Gibson SJ, Polak JM, Jaffray DC, Eisenstein SM. Morphological basis for back pain: the demonstration of nerve fibers and neuropeptides in the lumbar facet joint capsule but not in ligamentum flavum. J Orthop Res 1992;10:72-8.
6. Ashton IK, Roberts S, Jaffray DC, Polak JM, Eisenstein SM. Neuropeptides in the human intervertebral disc. J Orthop Res 1994;12:186-92.
7. Holmlund A, Ekblom A, Hansson P, Lind J, Lundeberg T, Theodorsson E. Concentrations of neuropeptides substance P, neurokinin A, calcitonin gene-related peptide, neuropeptide Y and vasoactive intestinal polypeptide in synovial fluid of the human temporomandibular joint. A correlation with symptoms, signs and artroscopic findings. Int J Oral Maxillofac Surg 1991;20:228-31.
8. Almay BGL, Johansson F, von Knorring L, Le Greves P, Terenius L. Substance P in CSF of patients with chronic pain syndromes. Pain 1988;33:3-9.
9. Toresson G, Brodin E, Wahlström A, Bertilsson L. Detection of N-terminally extended substance P but not of substance P in human cerebrospinal fluid - quantitation with HPLC - RIA. J Neurochem 1988;50:1701-7.
10. Clark JW, Senanayake PD, Solomon GD, Gallagher C. Substance P: correlation of CSF and plasma levels. Headache 1994;34:261-4.
11. Ahmed M, Srinivasan GR, Bjurholm A, Theodorsson E, Kreicbergs A. Extraction and quantitation of neuropeptides in bone by radio-immunoassay. A study in the rat. Regul Pept 51; 1994:179-88.
12. Calvino B, Courand JY, Besson JM. Prevaccination with diluted Freund adjuvant prevents the development of chronic pain and transient release of cerebrospinal fluid substance P in adjuvant arthritis in rats. Pain 1994;58:211-7.
13. Ahmed M, Bjurholm A, Kreicbergs A, Schultzberg M, Theodorsson E. Increased levels of substance P and calcitonin gene-related peptide in rat adjuvant arthritis. A combined immunohistochemical and radio-immunoassay analysis. Arthritis Rheum 1995;38:699-709.
14. Værøy H, Helle R, Førre Ø, Kåss E, Terenius L. Elevated CSF levels of substance P and high incidence of Raynad's phenomenon in patients with fibromyalgia: new features for dignosis. Pain 1988;32:21-6.
15. Russell IJ, Orr MD, Littman B, Vipraio GA, Alboukrek D, Michalek JE, et al. Elevated Cerebrospinal fluid levels of substance P in the fibromyalgia syndrome. Arthritis Rheum 1994;37:1593-601.
16. Nyberg K. Substance P synthesis by enzymatic fragment condensation using product-directed antibodies as molecular traps. J Mol Recognit 1988;1:59-62.
17. Liu Z, Welin M, Bragee B, Thörnwall M, Nyberg F. Elevated substance P level in cerebrospinal fluid from patients with fibromyalgia is contrasted by a decrease in Met-enkephalin-Arg-Phe. Analgesia 1995;1:543-7.
18. Tomlinson DR, Robinson JP, Compton AM, Keen P. Essential fatty acid treatment - effects on nerve conduction, polyol pathway and axonal transport in streptozotocin diabetic rats. Diabetologia 1989;32:655-9.
19. Nyberg F, Moberg U, Pernow C, Eriksson RB. HPLC and diode array detection for identification of peptides containing aromatic amino acids in studies of endorphine degrading activity in the human CSF. J Chromatogr A 1986;359:541-51.
20. Persson S, Jónsdóttir I, Thorén P, Post C, Nyberg F, Hoffman P. Cerebrospinal fluid dynorphin-converting enzyme activity is increased by voluntary exercise in the spontaneously hypertensive rat. Life Sci 1993;53:643-52.
21. Nyberg F, Lyrenäs L, Danielsson Å. Fingerprinting of molecular components in individual human cerebrospinal samples with a new micropurification system. J Chromatogr A 1991;548:311-8.
22. Arnalich F, de Miguel E, Perez-Ayala C, Martinez M, Vazquez JJ, Gijon-Banos J, et al. Neuropeptides and interleukin-6 in human joint inflammation relationship between intraarticular substance P and interleukin-6 concentrations. Neurosci Lett 1994;170:251-4.
23. Hernanz A, de Miguel E, Romera N, Perez-Ayala C, Gijon-Banos J, Arnalich F. Calcitonin-gene-related peptide II, substance P and vasoactive intestinal peptide in plasma and synovial fluid from patients with inflammatory joint disease. Br J Rheumatol 1993;32:31-5.
24. Sameshima K. Substance P-like immuno-reactivity in cerebrospinal fluid in lumbar disc herniation (in Japanese) Nippon Seikeigeka Gakkai Zasshi 1995;69:191-7.
25. Kawakami M, Tamaki T. Morphologic and quantitative changes in neurotransmitters in the lumbar spinal cord after acute or chronic mechanical compression of the cauda eqina. Spine 1992;17(3S):S13-S17.